Rinat Neuroscience competitive analysis

Latest publications and patents of Rinat Neuroscience New

Explore the latest publications and patents granted to Rinat Neuroscience, showcasing their recent innovations and technological advancements.

Last updated on: Sep 27, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Rinat Neuroscience

Dec 18, 2019Methods For Treating Pain By Administering An Antagonist Antibody Against The Nerve Growth Factor And An Opioid Analgesic, And Compositions Containing The SameRevoked
Oct 10, 2018Methods For Treating Bone Cancer Pain By Administering A Nerve Growth Factor Antagonistic AntibodyRevoked
Aug 2, 2017Methods For Treating Osteoarthitis Pain By Administering A Nerve Growth Factor Antagonist And Compositions Containing The SameRevoked

Explore Rinat Neuroscience's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 2, 2025
Patent NumberGrant DateTitleTotal Oppositions
Dec 18, 2019Methods For Treating Pain By Administering An Antagonist Antibody Against The Nerve Growth Factor And An Opioid Analgesic, And Compositions Containing The Same1
Oct 10, 2018Methods For Treating Bone Cancer Pain By Administering A Nerve Growth Factor Antagonistic Antibody1
Aug 2, 2017Methods For Treating Osteoarthitis Pain By Administering A Nerve Growth Factor Antagonist And Compositions Containing The Same2

Latest PTAB cases involving Rinat Neuroscience

Discover the latest PTAB cases involving Rinat Neuroscience, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Rinat Neuroscience with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
RINAT NEUROSCIENCE - 4 - - Non-Active
REGENERON PHARMACEUTICALS3893930Balanced
TEVA PHARMACEUTICALS20515 - 12Highly Aggressive